Neuromuscular Disease Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

Accelerate Predictive Drug Discovery with Scalable 3D Human Functional Models

Elevidys 3-Year Trial Data Show Sustained Outcomes in DMD Patients

January 30, 2026

Diagnostics News

HHS Expands Newborn Screening to Include Duchenne and MLD

December 19, 2025

AstraZeneca’s Gefurulimab Shows Significant Functional Gains for gMG Patients in Phase III

Imaavy, J&J’s New FcRn Blocker for gMG, Approved by FDA

FDA Greenlights Monthly IV Dosing for Alzheimer’s Med Leqembi

January 29, 2025

BlueRock Advances Bemdaneprocel Cell Therapy to Phase III Trial for Parkinson’s Disease

January 16, 2025

Clinical Trial News

AbbVie’s Tavapadon Reduces Motor Impairments in Phase III Parkinson’s Trial

December 11, 2024

Apitegromab’s Phase III Results Reveal Potential Motor Function Gains in SMA Patients

October 8, 2024

Clinical Trial News

Troriluzole: New Data Shows Delayed Disease Worsening in Spinocerebellar Ataxia Patients

October 3, 2024

Clinical Trial News

Tavapadon Shows Promise in Enhancing Daily Function for Early Parkinson’s Patients

September 30, 2024

World Alzheimer’s Day 2024: Innovative Therapies and More

September 18, 2024

Ocrevus Zunovo Subcutaneous Solution for MS Gains FDA Approval

September 16, 2024

Zunveyl Approved as New Oral Med for Alzheimer’s Disease

Vyvgart Hytrulo: A New Innovation in CIDP Treatment in Decades

Rystiggo Brings New Hope for Generalized Myasthenia Gravis Patients

Next Page »